 Zacks Investment Research lowered shares of OncoCyte NYSEAMERICAN:OCX from a hold rating to a sell rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. ... 